March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Oral Synthetic cis retinoid (QLT091001) treatment improves visual performance in an Leber Congenital Amaurosis (LCA) mouse model
Author Affiliations & Notes
  • Robin Roberts
    Anatomy & Cell Biol,
    Wayne State Univ Sch of Med, Detroit, Michigan
  • Bruce A. Berkowitz
    Anatomy/Cell Biol & Ophthal,
    Wayne State Univ Sch of Med, Detroit, Michigan
  • David P. Bissig
    Anatomy and Cell Biology, Wayne State Univ School of Med, Detroit, Michigan
  • Deepank Utkhede
    QLT Inc., Vancouver, British Columbia, Canada
  • Anthony Pepio
    QLT Inc., Vancouver, British Columbia, Canada
  • Footnotes
    Commercial Relationships  Robin Roberts, QLT Inc. (F, R); Bruce A. Berkowitz, QLT Inc. (F); David P. Bissig, QLT Inc. (F); Deepank Utkhede, QLT Inc. (E); Anthony Pepio, QLT Inc. (E)
  • Footnotes
    Support  QLT Inc.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3350. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robin Roberts, Bruce A. Berkowitz, David P. Bissig, Deepank Utkhede, Anthony Pepio; Oral Synthetic cis retinoid (QLT091001) treatment improves visual performance in an Leber Congenital Amaurosis (LCA) mouse model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3350. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Experimental mouse models are useful for evaluating the efficacy of new pharmaceutical treatments for abnormal visual cycle activity and associated retinal degeneration. We used a combination of two non-invasive

Methods: : OKT, which evaluates visual performance, and MRI, which measures central retinal thickness, in an Rpe65 mutant mouse model of LCA to investigate the effectiveness of orally administered QLT091001, a synthetic retinoid replacement for 11-cis retinal.Methods: A total of 40 rd12 mutant mice with defective Rpe65 isomerase activity (6-7 weeks of age, Jackson Labs) were treated in a masked fashion with vehicle or QLT091001 (oral gavage) and then light (n=20) or dark (n=20) adapted. A control group of 30 age-matched C57Bl/6 mice (C) was similarly treated with vehicle or QLT091001 (oral gavage), then light (n=9) or dark (n=19) adapted. Each mouse was studied with OKT (spatial frequency threshold [SF] and contrast sensitivity [CS]) and MRI.

Results: : The SF and CS data showed no differences between light and dark control groups, and were in agreement with previously published values. In rd12 mice, the following SF and CS patterns were found, and were mostly independent of light or dark adaption: Cvehc = Cdrug = rd12drug > rd12vehc; note "="means not significantly different and ">" or "<" means statistical significance on a 2-tailed test (at the 0.05 level). One exception to this pattern was CS in the light adapted groups: Cvehc and Cdrug less than or equal to rd12drug. Whole retinal thickness patterns, regardless of light and dark, were: Cvehc = Cdrug which were greater than rd12drug which was greater than rd12vehc. The relatively smaller retinal thickness of the rd12vehc group likely reflects a higher number of somewhat older (7 week) mice (and thus more retinal degeneration) relative to that in the other groups (~6 week).

Conclusions: : In this single time point study, QLT091001 clearly improved reduced visual performance in a mouse model of inherited retinal degeneration in a manner independent of retinal thickness. The combination of OKT and MRI provides a useful and informative approach for evaluating efficacy of pharmacological treatment in mouse models with visual cycle deficits.

Keywords: contrast sensitivity • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • photoreceptors: visual performance 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×